Acceleron Pharma (NASDAQ:XLRN)‘s stock had its “hold” rating reissued by stock analysts at Oppenheimer in a research report issued on Monday.
A number of other research firms also recently issued reports on XLRN. HC Wainwright lifted their target price on Acceleron Pharma from $57.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, November 7th. Cann reaffirmed a “hold” rating on shares of Acceleron Pharma in a research report on Tuesday, September 5th. Barclays lifted their target price on Acceleron Pharma from $42.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday, September 20th. UBS reaffirmed a “buy” rating and issued a $50.00 target price (up previously from $36.00) on shares of Acceleron Pharma in a research report on Tuesday, September 12th. Finally, ValuEngine raised Acceleron Pharma from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $44.56.
Shares of Acceleron Pharma (NASDAQ:XLRN) opened at $36.40 on Monday. Acceleron Pharma has a 12 month low of $23.07 and a 12 month high of $40.35.
Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.02. The business had revenue of $3.00 million for the quarter, compared to the consensus estimate of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. Acceleron Pharma’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.55) earnings per share. sell-side analysts forecast that Acceleron Pharma will post -2.65 EPS for the current fiscal year.
In other Acceleron Pharma news, major shareholder Corp /De/ Celgene purchased 745,592 shares of the stock in a transaction on Monday, September 25th. The shares were purchased at an average price of $37.00 per share, with a total value of $27,586,904.00. Following the completion of the transaction, the insider now directly owns 6,118,479 shares in the company, valued at $226,383,723. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.90% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. boosted its holdings in shares of Acceleron Pharma by 9.0% during the second quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock worth $121,719,000 after acquiring an additional 330,635 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Acceleron Pharma by 6.1% during the second quarter. Vanguard Group Inc. now owns 2,029,040 shares of the biopharmaceutical company’s stock worth $61,663,000 after acquiring an additional 116,705 shares during the period. Westfield Capital Management Co. LP boosted its holdings in shares of Acceleron Pharma by 46.6% during the second quarter. Westfield Capital Management Co. LP now owns 1,682,359 shares of the biopharmaceutical company’s stock worth $51,127,000 after acquiring an additional 534,440 shares during the period. Perceptive Advisors LLC boosted its holdings in shares of Acceleron Pharma by 127.2% during the third quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock worth $60,319,000 after acquiring an additional 905,000 shares during the period. Finally, Eagle Asset Management Inc. boosted its holdings in shares of Acceleron Pharma by 6.6% during the second quarter. Eagle Asset Management Inc. now owns 1,256,642 shares of the biopharmaceutical company’s stock worth $38,189,000 after acquiring an additional 77,683 shares during the period. 85.84% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://ledgergazette.com/2017/12/13/oppenheimer-reiterates-hold-rating-for-acceleron-pharma-xlrn.html.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.